BRPI1007883A2 - sal, e, cristal. - Google Patents

sal, e, cristal.

Info

Publication number
BRPI1007883A2
BRPI1007883A2 BRPI1007883A BRPI1007883A BRPI1007883A2 BR PI1007883 A2 BRPI1007883 A2 BR PI1007883A2 BR PI1007883 A BRPI1007883 A BR PI1007883A BR PI1007883 A BRPI1007883 A BR PI1007883A BR PI1007883 A2 BRPI1007883 A2 BR PI1007883A2
Authority
BR
Brazil
Prior art keywords
salt
crystal
Prior art date
Application number
BRPI1007883A
Other languages
English (en)
Inventor
Ikuo Kushida
Noritaka Kitazawa
Takuma Minamisono
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BRPI1007883A2 publication Critical patent/BRPI1007883A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1007883A 2009-02-26 2010-02-24 sal, e, cristal. BRPI1007883A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15561309P 2009-02-26 2009-02-26
JP2009043268 2009-02-26
PCT/JP2010/053372 WO2010098490A1 (en) 2009-02-26 2010-02-24 Salt of tetrahydrotriazolopyridine derivative and crystal thereof

Publications (1)

Publication Number Publication Date
BRPI1007883A2 true BRPI1007883A2 (pt) 2016-02-23

Family

ID=42126410

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007883A BRPI1007883A2 (pt) 2009-02-26 2010-02-24 sal, e, cristal.

Country Status (11)

Country Link
US (1) US8703954B2 (pt)
EP (1) EP2401277A1 (pt)
JP (1) JP5580816B2 (pt)
KR (1) KR20110118626A (pt)
CN (1) CN102333778B (pt)
AU (1) AU2010218667A1 (pt)
BR (1) BRPI1007883A2 (pt)
CA (1) CA2749702A1 (pt)
IL (1) IL213973A0 (pt)
MX (1) MX2011006782A (pt)
WO (1) WO2010098490A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261218B1 (en) * 2004-05-26 2013-04-03 Eisai R&D Management Co., Ltd. Imidazole compound for use as an intermediate in the production of cinnamide compounds
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
RU2515976C2 (ru) 2009-02-26 2014-05-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
KR102000382B1 (ko) 2015-02-03 2019-07-15 화이자 인코포레이티드 신규 시클로프로파벤조푸라닐 피리도피라진디온
CN113416188B (zh) * 2021-05-31 2022-12-13 河南偶联生物科技有限公司 一种[1,2,4]三唑并[1,5-a]吡啶化合物的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
EP2261218B1 (en) * 2004-05-26 2013-04-03 Eisai R&D Management Co., Ltd. Imidazole compound for use as an intermediate in the production of cinnamide compounds
TWI386207B (zh) 2005-11-24 2013-02-21 Eisai R&D Man Co Ltd 味啉類型之肉桂醯胺化合物
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
GEP20115139B (en) 2006-03-09 2011-01-10 Eisai R&D Man Co Ltd Polycyclic cinnamide derivative
TW200848054A (en) 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
CN102137855A (zh) * 2008-08-27 2011-07-27 卫材R&D管理有限公司 制备某些肉桂酰胺化合物的方法
US20120047601A1 (en) 2009-02-17 2012-02-23 The Regents Of The University Of California Method of Reducing Acetylation in Plants to Improve Biofuel Production
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
UY32464A (es) 2009-02-26 2010-09-30 Glaxo Group Ltd Nuevos compuestos de indazol
PT2401256E (pt) 2009-02-26 2013-05-13 Boehringer Ingelheim Int Compostos como antagonistas da bradicinina b1
WO2011006903A1 (en) 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators

Also Published As

Publication number Publication date
CN102333778A (zh) 2012-01-25
CN102333778B (zh) 2015-05-13
AU2010218667A1 (en) 2011-07-21
IL213973A0 (en) 2011-08-31
US20110275822A1 (en) 2011-11-10
CA2749702A1 (en) 2010-09-02
MX2011006782A (es) 2011-07-20
US8703954B2 (en) 2014-04-22
KR20110118626A (ko) 2011-10-31
JP2012519151A (ja) 2012-08-23
WO2010098490A1 (en) 2010-09-02
JP5580816B2 (ja) 2014-08-27
EP2401277A1 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
LTC2447254I2 (lt) Kristalai
BRPI1011886A2 (pt) solução contendo ácido hiplocloroso e métodos do uso do mesmo.
BRPI1014650A2 (pt) molas espiral-em-espiral e molas interiores.
DK2720617T4 (da) Vævsbeholder / beholderaggregat og dertil knyttet fremgangsmåde.
IT1400425B1 (it) Modified snrnas for use in therapy.
BRPI1012883A2 (pt) dispositivo intercorporal.
BR302012000450S1 (pt) Configuração aplicada em cápsula.
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
BR112012000281A2 (pt) proteína quimérica.
BRPI0807004A2 (pt) Sal
IT1396487B1 (it) Convogliatore.
IT1398747B1 (it) Oscillatore.
DK2442870T3 (da) Pyrazinooxazepin-derivater.
BRPI1008952A2 (pt) Composição herbicida.
BRPI1006990A2 (pt) planejador compartilhado
FR2942385B1 (fr) Grille-pain.
IT1394476B1 (it) Metodo per prevenire e controllare il biofouling.
BRPI1008675A2 (pt) grânulos.
IT1401887B1 (it) Elettrovalvola.
FR2946246B1 (fr) Fauteuil roulant.
IT1394461B1 (it) Dispositivo spollonatore.
BRPI0906688A2 (pt) Sal, e, cristal
ES1071429Y (es) Estratificado de aglomerado de silice-cuarzo, cristal y resinas
ES1073526Y (es) Almohada.
BRPI1007268A2 (pt) Combinações pesticidas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]